Mumbai: Zydus Lifesciences Limited , in partnership with MSN Laboratories Private Limited, announced on October 5, 2026, the launch of Riociguat Tablets in the United States. The tablets are available in 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg strengths. Market Launch Zydus and MSN are the first companies to introduce a generic version of Adempas® (riociguat) in the US market . The product was…
(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large…
Toronto, ON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Nox Peptides today announced an expanded focus on providing information and access to research peptide supplies for Canadian laboratories, academic…
Current Social Health Authority (SHA) contracts for county public health facilities will expire on October 14, 2026, as the government completes the transition to a new contracting framework covering…
